Venture Capital News | Private Equity News
Summary
I want to sincerely thank Brent, John and Nancy, along with all our investors for their support, as we continue to advance GDD3898 in the clinic," said J. Gordon Foulkes, Ph.D., CEO of Lipidio. "Our investors are highly encouraged by our recent clinical data and new insights into the multiple mechanisms induced by GDD3898 in the skin, which provide a strong rationale for expansion of our current indications. "GDD3898 has the potential to emerge as a first-in-class product for acne and sebaceous hyperplasia, filling a major gap in treatment and disrupting the market. John Maraganore, Ph.D., was the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from an early research platform forming over 20 major pharmaceutical alliances through to the global approval and commercialization of the first four RNAi therapeutic medicines. Brents first role as a senior executive in the healthcare sector began in 2003 at Schering-Plough as President of their Global Consumer Health Care Division.